Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCND2 | P30279 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22387976 | 0.78 | HRH4 (0.45) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL15357780 | 0.73 | HRH4 (0.46) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL12411105 | 0.71 | HRH4 (0.45) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL18898329 | 0.70 | MAPK8 (0.39) | MAPK8HRH4MAPK9MAPK10ABL1 | |
| SCHEMBL22388247 | 0.70 | HRH4 (0.44) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL12411110 | 0.69 | HRH4 (0.43) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL12411123 | 0.69 | HRH4 (0.43) | MAPK8HRH4MAPK9MAPK10ACACB | |
| SCHEMBL5516162 | 0.68 | TDP1 (0.44) | KCNH3 | |
| SCHEMBL7988856 | 0.66 | HRH4 (0.50) | MAPK8HRH4MAPK9MAPK10SYK | |
| SCHEMBL12411089 | 0.66 | HRH4 (0.43) | MAPK8HRH4ABL1LCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-07-30 | — | — | US | disclosed |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2018-06-14 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363257-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | MAPK8 2633/4885HRH4 1769/4885MAPK9 2059/4885 |
| US-20180161337-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAPK8 2510/4885HRH4 1939/4885MAPK9 2166/4885 |
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | MAPK8 2310/4885HRH4 1788/4885MAPK9 1953/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | MAPK8 2352/4885HRH4 1726/4885MAPK9 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.